Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Botulinum toxin in ophthalmology.

D Dunlop, G Pittar, C Dunlop

    Australian and New Zealand Journal of Ophthalmology
    |February 1, 1988
    PubMed
    Summary
    This summary is machine-generated.

    Type A Botulinum toxin, developed by Alan B. Scott, is invaluable for treating difficult ophthalmology conditions. Clinical use in 133 patients showed no significant complications in a large international trial.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    "It's your body… so it's just nice to know what they're putting in it" A qualitative study of women's views and experiences of caesarean section, antibiotic use and infection.

    BMC pregnancy and childbirth·2026
    Same author

    Multiple cerebral infarctions as a complication of cryptococcal meningitis in a patient undergoing single lung transplantation.

    Neurologia·2022
    Same author

    Clinical management of deviations in maternal temperature during labour and childbirth: an evidence-based intrapartum care algorithm.

    BJOG : an international journal of obstetrics and gynaecology·2022
    Same author

    Multiple cerebral infarctions as a complication of cryptococcal meningitis in a patient undergoing single lung transplantation.

    Neurologia·2021
    Same author

    The FAST-M complex intervention for the detection and management of maternal sepsis in low-resource settings: a multi-site evaluation.

    BJOG : an international journal of obstetrics and gynaecology·2021
    Same author

    Development of the FAST-M maternal sepsis bundle for use in low-resource settings: a modified Delphi process.

    BJOG : an international journal of obstetrics and gynaecology·2019
    Same journal

    Thomas a'Beckett Travers, 1902-1999.

    Australian and New Zealand journal of ophthalmology·2000
    Same journal

    Bowen's disease of the eyelid in a renal transplant recipient on immunosuppressants.

    Australian and New Zealand journal of ophthalmology·2000
    Same journal

    Linear IgA disease.

    Australian and New Zealand journal of ophthalmology·2000
    Same journal

    Ring keratitis from topical anaesthetic misuse.

    Australian and New Zealand journal of ophthalmology·2000
    Same journal

    Lamellar corneal autograft for corneal perforation.

    Australian and New Zealand journal of ophthalmology·2000
    Same journal

    Preretinal haemorrhages: an unusual manifestation of intravitreal amikacin toxicity.

    Australian and New Zealand journal of ophthalmology·2000
    See all related articles

    Area of Science:

    • Ophthalmology
    • Neurology
    • Pharmacology

    Background:

    • Type A Botulinum toxin was selected, researched, and developed for clinical application.
    • Ophthalmology presents numerous conditions that are challenging to treat effectively.

    Purpose of the Study:

    • To describe the indications, methods, and potential problems associated with Type A Botulinum toxin use.
    • To present the treatment outcomes for 133 patients.

    Main Methods:

    • Clinical application of Type A Botulinum toxin.
    • Review of treatment results from 133 patients.
    • Analysis of data from a multicentre international trial involving over 13,000 patients.

    Main Results:

    • Type A Botulinum toxin has proven invaluable across various disciplines, particularly in ophthalmology.

    Related Experiment Videos

  • Treatment of 133 patients demonstrated the efficacy and safety of the toxin.
  • A multicentre international trial involving over 13,000 patients reported no significant complications up to December 1986.

    • Conclusions:

    • Type A Botulinum toxin is a valuable therapeutic agent for challenging conditions in ophthalmology and other fields.
    • The clinical use of Type A Botulinum toxin is associated with a favorable safety profile, as evidenced by extensive clinical trials.